Navigation Links
Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
Date:5/6/2008

neration, oncology and inflammation. To date, Catalyst has established two discovery research and product development agreements with Wyeth Pharmaceuticals and Centocor Research & Development, Inc. Catalyst is privately-held with backing by leading venture firms including Burrill & Company, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures. For more information, please visit http://www.catbio.com.

Catalyst Biosciences, Inc.

Erik Wiberg

+1.650.266.8654

ewiberg@catbio.com

BCC Partners for Catalyst Biosciences, Inc.

Karen L. Bergman or Michelle Corral

+1.650.575.1509 or +1.415.794.8662


'/>"/>
SOURCE Catalyst Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
2. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
3. Neurocrine Biosciences Reports First Quarter 2008 Results
4. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
7. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
8. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
9. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... 26, 2014 China Nepstar Chain Drugstore Ltd. (NYSE: ... leading retail drugstore chain in China based on the ... financial results for the third quarter ended September 30, 2014. ... , Same store sales increased by 8.1% compared ... increased by 8.1% to RMB738.3 million (US$120.3 million) compared to ...
(Date:11/24/2014)... 2014 Luoxis Diagnostics, Inc., a subsidiary ... announced the presentation of three clinical and preclinical ... broadly applicable and robust research tool capable of ... response to injury, illness, or stress.  In all ... Luoxis, academic and pharmaceutical research partners, RedoxSYS was ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5
(Date:11/26/2014)... News) -- Parents need to take an active role ... warns. Parents must make sure sports-playing teens have ... Dodick, chair of the American Migraine Foundation and a ... Medicine in Scottsdale, Ariz. in an American Migraine Foundation, ... coach involved with teens sports needs to have appropriate ...
(Date:11/24/2014)... From embedded sensors and biometrics to elite training ... take center stage at the FitnessTech Summit , presented ... 2015 International CES® , January 6, 2015 in Las Vegas ... The bond between fitness and technology is stronger than ever ... more about the human body. , “Fitness technology has become ...
(Date:11/24/2014)... 2014 Global electrophysiology devices market ... 2020, according to a new study by Grand ... arrhythmias clubbed with growing global geriatric population base ... still in the budding stage, the electrophysiology devices ... rates in the recent times, with physicians increasingly ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Volpara ... version 1.2 at the 100th Annual Meeting of ... 30-December 5, 2014 (RSNA Booth 1752 – South ... of VolparaAnalytics and the rest of its innovative ... and VolparaDoseRT, which enable personalized measurements of volumetric ...
(Date:11/24/2014)... November 24, 2014 Residents of retirement ... in this year’s SENIORS GOT TALENT, an annual online ... From piano players to classic crooners, to seniors partying ... older adults are indeed living young. , “SENIORS GOT ... there’s a cash prize, has always been about highlighting ...
Breaking Medicine News(10 mins):Health News:Parents Need to Take Lead on Teen Concussion Prevention 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 2Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 3
... ... Health , ... (PRWEB) October 11, 2009 – The YWCA’s Week Without Violence kicks off today, acting as ... need for trained social workers throughout the world. Those interested becoming community support workers can ...
... - Mentalympians(TM) announced today, on this World Mental Health ... based in Australia, Canada, New Zealand, Scotland and the ... found on www.mentalympians.org . , Mentalympians has been ... operated through a network of mental health consumer groups. ...
... ... MAN (renewman.com), the first male hormone treatment program in the U.S., continues to ... symptoms, including andropause. A common condition among men ages 35 and older, reNEW ... doctor that can test, diagnose and treat hormone deficiencies through safe, self-administered treatments. ...
... with mental, neurological, and substance use (MNS) disorders in low ... the mental health "treatment gap." This week PLoS ... helping to close the gap. The series coincides with ... Mental Health, a collaborative initiative of the London School of ...
... InfoLogix, Inc. (Nasdaq: IFLG ), a leading ... and commercial industries, today announced that it has retained ... based in West Conshohocken, PA to assist InfoLogix in ... negotiates financing transactions at virtually every level of the ...
... (MIS), best known for regulating in utero sexual differentiation in ... according to a new study published online October 9 in ... associated with breast cancer risk, Joanne F. Dorgan, Ph.D., MPH, ... conducted a prospective case-control study of 309 participants who were ...
Cached Medicine News:Health News:YWCA's Week Without Violence Oct. 11-17 a Reminder That Community Support Workers Remain in High Demand 2Health News:World-first mental health media initiative announces inaugural Advisory Group 2Health News:Locate a Male Menopause Physician with reNEW MAN 2Health News:Locate a Male Menopause Physician with reNEW MAN 3Health News:Locate a Male Menopause Physician with reNEW MAN 4Health News:How should mental, neurological and substance use disorders be treated where resources are scarce? 2Health News:InfoLogix Announces News Related to its Recent Corporate Development Initiatives 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: